Remove Bacteria Remove Manufacturing Remove Protein
article thumbnail

Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape

Pharmaceutical Technology

Lyme disease is also known as borreliosis, which refers to the borrelia bacteria that cause the condition. A vaccine called Lymerix , then manufactured by SmithKline Beecham, was approved in the US in 1998 but was quickly withdrawn in 2002 due to insufficient custo mer demand. It is currently treated with antibiotics.

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023.

Bacterium 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer to Slash COVID-19 Vaccine Manufacturing Time by Almost 50 Percent

XTalks

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. coli bacteria. The bacteria are grown in large vats, with the process taking two weeks.

article thumbnail

Faba in Bakery: Going Egg-Free with Faba Beans

XTalks

Replacing eggs, especially in bakery products, remains a challenge for manufacturers. Plus, on a nutritional basis, they can enhance the overall protein content. Tests have focused on faba bean protein concentrate. Derived from chicory root, this fibre can support gut health by feeding beneficial intestinal bacteria.

Protein 52
article thumbnail

ADCs Pipeline Update: Avacta Partners with ADC Therapeutics

Roots Analysis

The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies.

article thumbnail

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Pfizer

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick.

article thumbnail

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

The Pharma Data

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.